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ABSTRACT 24	  
 25	  
There is increasing interest in the use of lipophilic copper (Cu)-containing complexes to 26	  
combat bacterial infections. In this work, we showed that Cu complexes with 27	  
bis(thiosemicarbazone) ligands [Cu(btsc)] exert antibacterial activity against a range of 28	  
medically significant pathogens. Previous work using Neisseria gonorrhoeae showed that 29	  
Cu(btsc) complexes may act as inhibitors of respiratory dehydrogenases of the electron transport 30	  
chain. We now show that these complexes are also toxic against a range of bacterial pathogens 31	  
some of which lack a respiratory chain. Respiration in Escherichia coli was slightly affected by 32	  
Cu(btsc) complexes but our results indicate that, in this model bacterium, the complexes act 33	  
primarily as agents that deliver toxic Cu ions efficiently to the cytoplasm. Although the 34	  
chemistry of Cu(btsc) complexes may dictate their mechanism of action, their efficacy depends 35	  
highly on bacterial physiology which is linked to the ability of the bacterium to tolerate Cu and 36	  
additionally, the susceptibility of the respiratory chain to direct inhibition by Cu(btsc) 37	  
complexes.  The physiology of N. gonorrhoeae, including multidrug-resistant strains, makes it 38	  
highly susceptible to damage by Cu ions and Cu(btsc) complexes, highlighting the potential of 39	  
Cu(btsc) complexes as a potential treatment against this significant bacterial pathogen. 40	  
 41	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  43	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INTRODUCTION 44	  
 45	  
Copper (Cu) is an essential trace micronutrient in bacteria but it is bacteriotoxic in 46	  
excess. Nutrient Cu inserts into specific high-affinity sites in proteins, or it forms complexes with 47	  
low molecular weight thiols such as glutathione. As a consequence, the concentration of “free” 48	  
Cu ions in cells has been estimated to be vanishingly low (sub-femtomolar) (1). Any excess Cu 49	  
beyond this normal binding capacity may be mislocated to nonspecific and low-affinity metal ion 50	  
binding sites, thereby inactivating crucial enzymes and interfering with normal metabolism (2). 51	  
As the mid-potential of the Cu(II)/Cu(I) redox couple is biologically accessible, these weakly 52	  
bound Cu ions can also cause further toxicity by catalyzing gratuitous electron transfer and 53	  
promoting redox stress (3). The widespread damage caused by excess Cu ions is termed Cu 54	  
poisoning. Almost all bacterial species, including those that have no apparent use for Cu, possess 55	  
homeostatic systems that protect them against an excess of this ion (4). These systems consist 56	  
typically of a Cu ion efflux pump that operates under the control of a Cu-specific transcriptional 57	  
regulator.  58	  
As a result of its chemistry, Cu is considered a promiscuous or broad-spectrum 59	  
antimicrobial but there is concern regarding its universal toxicity. In the pre-antibiotic era, 60	  
simple ionic Cu salts were used to treat a variety of infections (5), but these salts are now 61	  
associated with significant toxicity (6). The difficulty in delivering bactericidal Cu at doses that 62	  
are nontoxic to human tissues may explain the failure to translate Cu-based therapeutics into the 63	  
modern medical setting. The emergence of bacteria with resistance to classical antibiotics, 64	  
combined with the paucity of new compounds in the pipeline, has now renewed interest in the 65	  
development of Cu as an antimicrobial (7-9). This research is motivated further by recent 66	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findings that physiological Cu may be harnessed as a direct antimicrobial in innate immune cells 67	  
(10, 11).  68	  
Ionic Cu salts have limited ability to cross membranes as their translocation relies on 69	  
specific transport proteins, and so they have little potential to be developed as anti-infective 70	  
drugs. Cu ions generally show restricted penetration into target tissues and bacteria, and thus 71	  
exceptionally high concentrations are needed to achieve a bactericidal effect in vitro and in vivo. 72	  
To assist in the delivery of Cu ions across lipid membranes, several lipophilic ligands or 73	  
proligands have been developed (9, 12). These molecules are termed ‘Cu ionophores’ for their 74	  
ability to act as carriers of Cu ions.  75	  
Of interest in this work are bis(thiosemicarbazone) ligands that bind Cu(II) as small, 76	  
uncharged, lipophilic, and stable complexes (Cu(btsc), Figure 1). We and others have shown that 77	  
Cu(btsc) complexes exert antimicrobial activity against several human pathogens, including 78	  
Gram-negative bacteria such as Neisseria gonorrhoeae (13) and Mycobacterium tuberculosis 79	  
(14), as well as the Gram-positive bacterium Staphylococcus aureus (15). However, the 80	  
mechanism of antibacterial action of Cu(btsc) complexes has not been examined fully. Although 81	  
it is assumed that they operate as Cu ionophores (14, 15), we have shown that Cu(btsc) 82	  
complexes can also act as direct respiratory inhibitors in N. gonorrhoeae (13). Here we describe 83	  
experiments using Escherichia coli that are aimed at determining whether Cu(btsc) complexes 84	  
act primarily by inhibition of the respiratory chain or by delivery of bioavailable Cu ions. We 85	  
also assess the susceptibility of a range of bacterial pathogens to these complexes, including 86	  
multidrug-resistant strains of N. gonorrhoeae. 87	  
 88	  
MATERIALS AND METHODS 89	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 90	  
Cu stocks. Stocks of aqueous Cu salts, supplied as CuCl2 or Cu(NO3)2, were prepared in 91	  
deionised water and their concentrations were standardised using bathocuproine disulfonate as 92	  
described elsewhere (16). The two salts were used interchangeably in experiments. Stocks of 93	  
Cu-pyrithione, Cu-neocuproine, and Cu-disulfiram complexes were prepared in DMSO by 94	  
mixing standardised CuCl2 with 2.5 molar equivalents of the respective free ligands. Stocks of 95	  
Cu(atsm) and Cu(gtsm) were prepared in neat DMSO and standardised using their solution 96	  
absorbance in DMSO (Cu(atsm): λmax 457 nm, ε 7200 M-1 cm-1; Cu(gtsm): λmax 472 nm, ε 8700 97	  
M-1 cm-1). DMSO was used as a vehicle control in all experiments.  98	  
Strains and growth conditions. N. gonorrhoeae strains (Table 3) were grown on GC 99	  
agar (Oxoid) supplemented with 1 v/v % IsoVitaleX (Becton Dickinson). Liquid cultures were 100	  
prepared in GC broth supplemented with IsoVitaleX and 0.042 w/v % sodium bicarbonate. E. 101	  
coli strains MG1655 (laboratory strain K-12) and EC958 (fluoroquinolone-resistant strain 102	  
ST131), and Salmonella enterica sv. Typhimurium SL1344 were propagated on LB agar or 103	  
broth. Haemophilus influenzae RdKw20 was propagated on BHI medium (Oxoid) containing 10 104	  
µg/mL NAD+ and 10 µg/mL hemin. Streptococcus pneumoniae D39 was propagated on THY 105	  
base (Oxoid) containing 10 U/mL catalase. S. aureus strain ATCC 22913 (methicillin-sensitive), 106	  
and SR2852 (methicillin-resistant) strains were grown on Tryptic Soy medium (Becton 107	  
Dickinson). Lactobacillus acidophilus NCFM was grown on L-MRS agar (Oxoid) under 108	  
anaerobic growth conditions. All bacteria were grown for 12 – 16 h at 37 oC. N. gonorrhoeae, S. 109	  
pneumoniae, and S. aureus were grown in the presence of 5 v/v % atmospheric CO2. Anaerobic 110	  
growth was performed in an anaerobic jar containing an AnaeroGen sachet (Oxoid).  111	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Determination of MICs. MICs were determined by agar dilution method. Briefly, 112	  
bacterial lawns from an overnight agar culture were resuspended in the appropriate broth to 107 – 113	  
108 CFU/mL and 5 µL of each dilution was spotted onto new solid media containing various 114	  
concentrations of the desired Cu source. The amount of DMSO was maintained at 0.5 v/v %. The 115	  
MIC value was defined to be the minimum concentration at which no growth was visible after 24 116	  
h.  117	  
Assays of gonococcal killing kinetics. N. gonorrhoeae lawns from an overnight agar 118	  
culture were resuspended in broth to an OD600 of 0.1 (ca. 107 CFU/mL). Cu complexes were 119	  
added to the desired final concentration and the mixtures were incubated at 37 oC with gentle 120	  
shaking. Survival was monitored for up to 7 h by conventional colony counting.  121	  
Measurement of intracellular Cu levels in E. coli. E. coli was resuspended in broth to 122	  
an OD600 of 0.1 (ca. 108 CFU/mL) and used to seed fresh solid media containing the desired Cu 123	  
source. After an overnight growth, bacteria were harvested, washed once in PBS containing 10 124	  
v/v % DMSO, once in PBS containing 1 mM EDTA, and finally once in PBS without any 125	  
additive. The final pellet was dissolved in conc. nitric acid. Amounts of Cu and other transition 126	  
metal ions were determined by Inductively-Coupled Plasma Optical Emission Spectrometry (ICP 127	  
OES). Results were standardised to total biomass as represented by total protein content. The 128	  
amount of protein was assayed using the Quanti BCA Kit (Sigma).  129	  
To evaluate the antibacterial activity of the Cu complexes under the same conditions, the 130	  
initial inoculum was diluted serially up to 10-7 and 5 µL of each dilution was plated out on 131	  
duplicate solid media containing the various Cu sources. Visible colonies were enumerated after 132	  
24 h to determine the efficiency of plating. 133	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Assays of β-galactosidase activity in E. coli. The promoter region of copA from E. coli 134	  
MG1655 (150 bp upstream from the translation start codon ATG) was amplified using the primer 135	  
pairs PcopA-F (5’-CATCAGGGATTCAGATAAATGTCTAATCCTGA-3’) and PcopA-R 136	  
(5’-CTGATGAAGCTTAAAACACTCCTTTAAGACAG-3’). The PCR product was cloned 137	  
between the BamHI and HindIII sites of the low-copy vector pQF50 containing a promoterless 138	  
lacZ gene (17). The resulting pQF50::PcopA plasmid was transformed into E. coli DH5α. 139	  
Colonies that were blue on agar plates containing ampicillin (100 µg/mL), X-gal (40 µg/mL), 140	  
and CuCl2 (500 – 1000 µM) were selected and grown to the mid-exponential phase. Cultures 141	  
were challenged with Cu complexes for 0 – 120 min without any shaking. β-galactosidase 142	  
activities were measured using ortho-nitrophenyl-β-galactoside following procedures for 143	  
standard Miller assay. Raw values of β-galactosidase activity were normalised to OD600. Results 144	  
were expressed as fold-induction over the uninduced control at the same time point. 145	  
Assays of respiration in E. coli. E. coli was cultured to the mid-exponential phase, 146	  
harvested, resuspended in LB to 10% of the original volume, and kept on ice. Respiration was 147	  
measured at 35 oC in 2 mL of broth containing 50 µM of Cu salt, Cu(gtsm), or Cu(atsm). 148	  
Consumption of O2 was initiated by adding 10 µL of the bacterial suspension. Respiration was 149	  
monitored for 15 min using an S1/Mini Clark-type oxygen electrode (Hansatech Instruments) in 150	  
conjunction with an Oxytherm control unit.  151	  
E. coli membrane vesicles were isolated as described previously for N. gonorrhoeae (13). 152	  
Rates of NADH oxidation were measured spectrophotometrically at 340 nm following 153	  
procedures described previously for submitochondrial particles from rat liver (18). 154	  
Assays of using cervical epithelial cells. Immortalised and adherent ME-180 cervical 155	  
epithelial cells (ATCC® HTB33™) were cultured routinely according to manufacturer’s 156	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instructions in McCoy's 5a Modified Medium (ATCC 30-2007) containing fetal bovine serum 157	  
(10 v/v %, ATCC 30-2020), and penicillin and streptomycin (100 IU/mL and 100 µg/mL, 158	  
respectively, Corning-Cellgro 30-002-CI), Cells were seeded at 1 x 106 cells/mL and allowed to 159	  
adhere overnight. The resulting monolayers were transitioned into fresh medium containing 160	  
Cu(gtsm), Cu(atsm), or Cu salt. The concentration of DMSO in all samples was 0.1 v/v %. After 161	  
24 h, the supernatant was collected and checked for cells that may have detached during 162	  
treatment. The remaining adherent cells were allowed to recover for 1 – 2 h and subsequently 163	  
brought into suspension using trypsin/EDTA. Trypan Blue (0.2 w/v %) was added and cells were 164	  
enumerated in a hemocytometer. 165	  
 166	  
RESULTS 167	  
 168	  
Antibacterial activity of Cu(btsc) complexes towards select bacterial pathogens. 169	  
Two prototypes of the Cu(btsc) family, Cu(gtsm) and Cu(atsm) (Figure 1), exerted dose-170	  
dependent antibacterial activity against N. gonorrhoeae strain 1291 (13). Both complexes were 171	  
effective at concentrations where the unmetallated H2btsc ligands and the uncomplexed or ‘free’ 172	  
aqueous Cu2+ ions were ineffective (Table 1) (13). The MICs were 0.1 µM (0.03 µg/mL) for 173	  
Cu(gtsm) and 1 µM (0.3 µg/mL) for Cu(atsm) (Table 1). We also evaluated the anti-gonococcal 174	  
activities of additional Cu ionophores, including Cu-disulfiram, Cu-neocuproine, and 175	  
Cu-pyrithione. The MIC value for Cu-pyrithione (0.13 µM, ca. 0.04 µg/mL) was comparable to 176	  
that for Cu(gtsm) (Table 1). For this study, we examined Cu(gtsm) in greater depth as the 177	  
availability of the structural analogue Cu(atsm) with a lower efficacy allowed us to probe the 178	  
mode of action in more detail. 179	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The mode of action of Cu(gtsm) and Cu(atsm) against N. gonorrhoeae was bactericidal. 180	  
Complete killing of N. gonorrhoeae (~107 CFU/mL) by 1 µM of Cu(gtsm) was achieved within 181	  
1.5 h, while an equal dose of Cu(atsm) required at least 5 h to elicit an equivalent effect (Figure 182	  
2). By contrast, ionic Cu salts displayed no bactericidal activity within this time period (Figure 183	  
2). The relative MICs and killing kinetics established that Cu(gtsm) and Cu(atsm) were more 184	  
toxic than Cu salts, and that Cu(gtsm) was more toxic than Cu(atsm).  185	  
Cu(gtsm) and Cu(atsm) were also effective against several additional and unrelated 186	  
bacterial pathogens, including S. aureus (methicillin-sensitive and resistant strains), S. 187	  
pneumoniae, and H. influenzae, but at MICs that were appreciably higher (Table 2). E. coli 188	  
(fluoroquinolone-sensitive and resistant strains) and S. Typhimurium were the most resistant. In 189	  
the case of E. coli, bacterial growth was observed even at Cu(gtsm) concentrations as high as 25 190	  
µM (7.5 µg/mL), although there was a 1000-fold reduction in the plating efficiency when 191	  
compared with the untreated control (Figure S1 in Supplemental Material). In comparison, 192	  
exposure to 25 µM of Cu(atsm) had no effect (Figure S1). Due to limited solubility of Cu(btsc) 193	  
complexes, higher concentrations were not tested. 194	  
Since N. gonorrhoeae and E. coli represented the most susceptible and most resistant test 195	  
organisms, respectively, they were examined further; the former because it may be a promising 196	  
target for Cu- and Cu(btsc)-based therapeutics and the latter because its resistance properties and 197	  
its amenability to molecular analysis might help in determining the mode of Cu(btsc) action.  198	  
 199	  
Inhibition of respiration in E. coli by Cu(btsc) complexes and antibacterial activity under 200	  
anaerobic growth conditions. 201	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Recently, we showed that Cu(gtsm) and, to a lesser extent, Cu(atsm) suppressed aerobic 202	  
respiration in N. gonorrhoeae (13) and mitochondria (18). Within the electron transport chain, 203	  
NADH dehydrogenases (Nuo or Complex I (H+-translocating) and Nqr (Na+-translocating)) were 204	  
identified as the primary targets of inhibition. Inhibition occurred at or near the site of 205	  
ubiquinone reduction and it was independent of the release of ‘free’ Cu ions (18). Instead, an 206	  
intact Cu(gtsm) or Cu(atsm) molecule was determined to be the inhibitory species. Subsequently, 207	  
we proposed that the action of Cu(btsc) complexes as respiratory inhibitors may be a major 208	  
mechanism of their antibacterial activity (13). However, our present work has now shown that 209	  
these complexes were also effective against bacteria that do not respire such as S. pneumoniae 210	  
(Table 2).  211	  
Cu(gtsm) (50 µM) also suppressed respiration in E. coli, as indicated by a decrease in the 212	  
total amount of O2 consumed after 15 min, while equal concentrations of Cu salts or Cu(atsm) 213	  
had no effect (Figure 3A). E. coli possesses two respiratory NADH dehydrogenases, Nuo and 214	  
Ndh-2 (single-subunit flavoenzyme, does not translocate H+) (19), which may be targets of 215	  
Cu(gtsm) inhibition. However, Cu(gtsm) only weakly suppressed the rates of NADH oxidation 216	  
in isolated membrane vesicles containing both Nuo and Ndh-2 (Figure 3B). The I50 value was 217	  
extrapolated to be >130 µM (Figure S2), well beyond the solubility limit for Cu(gtsm) indicating 218	  
that the NADH dehydrogenases in E. coli were not major targets of respiratory inhibition by 219	  
Cu(gtsm). This finding was not altogether surprising, as Nuo and Ndh-2 in E. coli were also less 220	  
sensitive to inhibition by the classical Nuo or Complex I antagonist, rotenone. This difference 221	  
has been ascribed to subtle structural differences at or near the sites of ubiquinone reduction (20). 222	  
More importantly, Cu(gtsm) was also inhibitory to E. coli under anaerobic growth 223	  
conditions, as evidenced by a curve of plating efficiency that was essentially indistinguishable to 224	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that obtained under aerobic growth conditions (Figure S1). Therefore, unlike the situation in N. 225	  
gonorrhoeae (13), inhibition of aerobic respiration did not appear to contribute significantly to 226	  
the antibacterial activity of Cu(gtsm) against E. coli.  227	  
 228	  
Boosting of intracellular Cu levels by Cu(btsc) complexes. 229	  
The MICs for both Cu(gtsm) and Cu(atsm) were consistently lower than those for ionic 230	  
Cu salts by >2 orders of magnitude (Table 2). Unlike charged Cu ions, neutral Cu(btsc) 231	  
complexes are presumed to be readily membrane-permeable. Thus, treatment with Cu(btsc) 232	  
complexes would be expected to drive a greater accumulation in bacterial Cu contents when 233	  
compared with equal doses of Cu salts. However, previous analyses of total Cu by ICP OES 234	  
detected no such effect in N. gonorrhoeae (13). As N. gonorrhoeae was killed by low nanomolar 235	  
doses of Cu(btsc) complexes (Tables 1 and 2), we reasoned that any gain in intracellular Cu 236	  
might remain below the detection limit of these measurements. 237	  
The analyses of Cu content were repeated here using E. coli because of its ability to 238	  
tolerate micromolar concentrations of Cu(gtsm) and Cu(atsm) (Table 2). First, we established 239	  
that treatment with 10 – 15 µM of ionic Cu salts increased the total Cu content of E. coli by 2 – 240	  
3-fold when compared with the untreated control (Figure 4A). These amounts of intracellular Cu 241	  
were non-inhibitory and there was no decrease in plating efficiency (Figure 4B). Treatment with 242	  
similar doses of Cu(atsm) induced a comparable rise in Cu levels (Figure 4A), again without any 243	  
loss in plating efficiency (Figures 3B). By contrast, exposure to equal doses of Cu(gtsm) led to a 244	  
greater accumulation of Cu that was 5 – 8-fold higher relative to the unchallenged control 245	  
(Figure 4A). This modest boost in intracellular Cu levels was correlated with an antibacterial 246	  
effect and there was a 5 – 10-fold reduction in plating efficiency (Figure 4B). There was no 247	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change in the levels of other transition metal ions (Figure S3), confirming that the antibacterial 248	  
effect of Cu(gtsm) was Cu-dependent.  249	  
 250	  
Dissociation of Cu from Cu(btsc) complexes as bioavailable ions. 251	  
The relative ability of Cu(gtsm) and Cu(atsm) to promote intracellular accumulation of 252	  
Cu matched their relative antibacterial potency (Table 2). In fact, for all bacterial pathogens that 253	  
we tested, the MICs of Cu(gtsm) were invariably lower than those of Cu(atsm) (Table 2). This 254	  
result was in line with the proposed action of Cu(btsc) complexes as Cu carriers. The Cu(II) 255	  
center in Cu(btsc) is bound strongly and is not thought to be dissociated as Cu(II) ions. Instead, 256	  
Cu is released as Cu(I) (see Figure 8 below). This occurs upon reduction of the Cu(II) center by 257	  
biological reductants such as thiols (21). As a consequence of a higher Cu(II)/Cu(I) reduction 258	  
mid-point potential for Cu(gtsm) (Figure 1), dissociation of Cu(I) ions from Cu(gtsm) is assured 259	  
(21). By contrast, Cu(atsm) possesses a lower Cu(II)/Cu(I) mid-point potential, and thus 260	  
dissociation of Cu(I) ions from Cu(atsm) is not thought to occur except in hypoxic cells (22, 23). 261	  
The final amounts of intracellular Cu delivered by Cu(gtsm) and Cu(atsm) (< 25 ng 262	  
Cu/mg protein) were well below the maximum tolerable capacity of E. coli. Exposure to higher 263	  
doses of Cu salts (1500 µM) led to the accumulation of Cu to 200 ng Cu/mg protein (Figure S3), 264	  
but the plating efficiency of bacteria remained unchanged (Figure S1). This apparent disconnect 265	  
between total Cu content and antibacterial potency has been observed previously (13, 15). Here it 266	  
must be noted that ICP OES measurements do not differentiate between Cu that is captured by 267	  
the bacterium as bioavailable ions and Cu that remains coordinated as a Cu(btsc) complex.  268	  
To examine the dissociation of Cu from Cu(btsc) complexes as bioavailable ions, we 269	  
exploited the innate bacterial response to excess Cu. The system in E. coli is particularly well 270	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characterized (Figure 5A) and amenable for analysis. In E. coli, increased intracellular Cu is 271	  
sensed by the Cu(I)-specific transcriptional regulator CueR. In turn, CueR activates the 272	  
expression of CopA, a membrane-bound P-type ATPase that exports Cu(I) out of the cytoplasm, 273	  
and CueO, a periplasmic cuprous oxidase that oxidizes Cu(I) to the less toxic form Cu(II) (Figure 274	  
5A) (24). In this work, we fused a plasmid-borne, promoterless lacZ transcriptional reporter gene 275	  
with the promoter region of the copA gene (PcopA-lacZ, Figure 5A) and subsequently tested the 276	  
ability of ionic Cu salts, Cu(gtsm) and Cu(atsm) to induce β-galactosidase activity in E. coli. 277	  
This opportunity was not available with N. gonorrhoeae, as the CueR regulon or any other 278	  
recognizable Cu detoxification system is absent, with the sole exception of the efflux pump 279	  
CopA (25). Furthermore, unlike the copA gene in E. coli, expression of gonococcal copA is 280	  
controlled by an unidentified mechanism that does not appear to involve Cu (25). 281	  
Addition of Cu salts into the growth medium led to a dose-dependent increase in 282	  
β-galactosidase activity (Figure 5B). No induction was observed in the presence of other 283	  
transition metal ions (Figure 5C), thus validating the Cu-specific response of the PcopA-lacZ 284	  
fusion. More importantly, exposure to Cu(gtsm) also led to a robust induction of β-galactosidase 285	  
activity (Figure 5B), consistent with the intracellular release of bioavailable Cu ions from 286	  
Cu(gtsm), presumably as Cu(I). While the minimum dose of Cu salts required for induction was 287	  
> 1 µM, activation by Cu(gtsm) was observed at concentrations as low as 0.1 µM (Figure 5B). 288	  
Moreover, activation of PcopA-lacZ by Cu(gtsm) was rapid and the maximum response was 289	  
achieved as early as 20 min post-exposure (Figure 5D). There was a detectable decrease in this 290	  
response after 40 min, presumably due to the toxic effects of Cu(gtsm) or the dissociated Cu(I) 291	  
ion. By comparison, induction of PcopA-lacZ by ionic Cu salts occurred gradually over a period 292	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of at least 2 h (Figure 5D). These findings further confirmed that Cu(gtsm) is a more efficient 293	  
source of intracellular bioavailable Cu(I) ions than uncomplexed Cu salts. 294	  
As mentioned earlier, the Cu center in Cu(atsm) is considered to display less dissociation 295	  
intracellularly when compared to Cu(gtsm) (21-23). However, like Cu(gtsm), Cu(atsm) also 296	  
activated the PcopA promoter as detected by an increase in β-galactosidase activity (Figure 5B). 297	  
The maximum magnitudes of activation by Cu(atsm) and Cu(gtsm) were comparable (Figures 298	  
4B and 4D). These results provided strong evidence that Cu was also released from Cu(atsm) as 299	  
bioavailable Cu(I) ions. However, when compared with Cu(gtsm), there was a reproducible lag 300	  
in the response to Cu(atsm) and a maximum was achieved only after 80 min of exposure (Figure 301	  
5D). Taken together, this data is consistent with the view that Cu(gtsm) is a more efficient Cu 302	  
delivery agent than Cu(atsm).  303	  
 304	  
Susceptibility of Cu tolerance mutants of E. coli to Cu(btsc) complexes and dissociation of 305	  
Cu ions in the cytoplasm. 306	  
Activation of the PcopA promoter by Cu(gtsm) and Cu(atsm) implied that expression of 307	  
copA and export of Cu(I) from the cytoplasm by CopA may mediate bacterial resistance to these 308	  
Cu complexes. To test this proposal, we examined whether inactivation of copA in E. coli 309	  
enhanced susceptibility to Cu(btsc) complexes. The effect of copA (and cueO) mutation on Cu 310	  
tolerance in E. coli has been well characterised previously (26, 27). In this work, we confirmed 311	  
that the copA mutant strain of E. coli was more sensitive to inhibition by Cu salts when 312	  
compared with the isogenic parent strain (Figure 6A), consistent with the established role of 313	  
CopA in tolerance to Cu ions. Importantly, the copA mutant was also sensitized to Cu(gtsm) and 314	  
no bacterial growth was observed above 5 µM (Figure 6B). This reduction in MIC when 315	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compared with the wild type (MIC >25 µM, Table 2) supports a role for Cu(I) ion efflux by 316	  
CopA in the detoxification of Cu(gtsm).  317	  
A cueO mutant strain of E. coli that lacks the periplasmic cuprous oxidase (Figure 5A) 318	  
also displayed a Cu salt-sensitive phenotype (Figure 6A). However, susceptibility of the cueO 319	  
mutant to Cu(gtsm) was indistinguishable from that of the wild type (Figure 6B). This result 320	  
indicated that, although oxidation of toxic Cu(I) to Cu(II) by CueO was required for tolerance to 321	  
free Cu ions and salts, it was not essential for resistance to Cu(gtsm). While CopA protects 322	  
against cytoplasmic Cu toxicity, CueO operates in the periplasm (Figure 5A). Thus, the apparent 323	  
requirement for CopA but not CueO indicated that dissociation of bioavailable Cu ions from 324	  
Cu(gtsm) occurred specifically in the cytoplasm and not in the periplasm. 325	  
In the case of Cu(atsm), there was no reduction in its MIC against the copA mutant 326	  
(Figure 6C). However, there was a noticeable decrease in colony size (Figure 6C), which was 327	  
consistent with a suppressed growth rate in liquid medium (Figure S4). These observations 328	  
suggest that the CopA efflux pump may also confer tolerance to Cu(atsm), although the effect 329	  
was subtle presumably because generation of bioavailable Cu ions from this complex was 330	  
inefficient. As expected, Cu(atsm) had no observable effect on the cueO mutant (Figure 6C).  331	  
The toxic effects of salts of Cu and other metal ions are known to be affected severely by 332	  
speciation or potential binding and buffering by components of the culture medium (28). Thus, it 333	  
is often the case that the less complex the medium, the lower the MICs. The inhibitory effects of 334	  
Cu(gtsm) and Cu(atsm) on the growth of the most sensitive mutant, copA, were similar when 335	  
tested in LB or in M9 medium (Figure S4), suggesting that there was minimal release of free Cu 336	  
ions from Cu(btsc) complexes in the extracellular medium. 337	  
 338	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Efficacy of Cu(btsc) complexes against MDR strains of N. gonorrhoeae.  339	  
The demonstrated action of Cu(gtsm) and Cu(atsm) as carriers of Cu ions and the 340	  
established mechanism of Cu ion poisoning by mis-metallation of enzymes and promotion of 341	  
redox stress are distinct from the known modes of action of conventional antibiotics. Thus, we 342	  
propose that these complexes may represent a promising new strategy for the treatment of 343	  
antibiotic-resistant bacterial infections. Their low relative MICs against N. gonorrhoeae (Table 344	  
2) indicated that Cu(gtsm) and Cu(atsm) were highly potent against this bacterium. Therefore, 345	  
we extended this work to test the potential for Cu(btsc) complexes to be used against multidrug-346	  
resistant (MDR) N. gonorrhoeae. 347	  
Cu(gtsm) showed robust activity against several antibiotic-resistant isolates of N. 348	  
gonorrhoeae (Table 3), including the MDR strains F89 (29) and H041 (30), which are resistant 349	  
to β-lactams (except carbapenems), fluoroquinolones, macrolides, tetracycline, chloramphenicol, 350	  
trimethoprim-sulfamethoxazole, chloramphenicol, and nitrofurantoin. The MICs for these 351	  
isolates were comparable to that for the drug-susceptible strain 1291 (Table 3), suggesting that 352	  
the antibacterial activity of Cu(gtsm) was not diminished by enzymes and transporters that 353	  
confer resistance to other antibiotics. In N. gonorrhoeae, these include the pilus secretin PilQ 354	  
(31) and the MtrFCDE multidrug efflux pump system (32). To test this hypothesis, we 355	  
determined the MICs of Cu(gtsm) for strains KH15 and DW120, which are isogenic mutants of 356	  
the drug-susceptible strain FA19 that express higher basal levels of the MtrCDE pump (32). 357	  
Although these strains showed increased resistance to multiple antibiotics and antimicrobial 358	  
peptides when compared with the parent strain (32), they were no less susceptible to Cu(gtsm) 359	  
(Table 3).  360	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Like Cu(gtsm), Cu(atsm) was also effective against MDR isolates and MtrFCDE-361	  
overexpressing strains of N. gonorrhoeae (Table 3). However, there were > 2-fold increases in 362	  
MICs when compared to the antibiotic-susceptible strains (Table 3). This loss of efficacy 363	  
indicated that Cu(atsm) may be a substrate for the MtrCDE efflux pump. Consistent with this 364	  
proposal, inactivation of the mtrD gene (strain KH14) (33) led to a modest but reproducible 365	  
decrease in the MIC of Cu(atsm) when compared to the isogenic parent strain (FA19) (Table 3). 366	  
The loss of mtrD did not have any effect on the MIC of Cu(gtsm) (Table 3). 367	  
 368	  
Viability of host epithelial cells in the presence of antimicrobial doses of Cu(btsc) 369	  
complexes. 370	  
To ascertain the potential of Cu and Cu(btsc) complexes as a clinically useful anti-371	  
gonococcal agent, we examined whether Cu(gtsm) and Cu(atsm) exert an effect on the viability 372	  
of cervical epithelial cells (ME-180 epithelial cells) in vitro. As shown in Figure 7, incubation of 373	  
ME-180 monolayers with up to 0.5 µM of Cu(gtsm) and 5 µM of Cu(atsm) (ca. 5X the MIC 374	  
against N. gonorrhoeae, see Table 3) for 24 h did not result in loss of cell viability. There was no 375	  
loss in cell numbers (Figure 7) and more than 95% of these cells retained the ability to exclude 376	  
Trypan Blue (Figure 7). Under our experimental conditions, the ME-180 cell line did not 377	  
withstand treatment with DMSO beyond 0.1 v/v %. Thus, higher concentrations of the Cu 378	  
complexes were not tested because of poor solubility in the culture media without DMSO. 379	  
Nevertheless, previous work with human prostate epithelial cells were had used up to 100 µM 380	  
without any observable loss of viability (34), indicating a potential therapeutic index of 1000 for 381	  
N. gonorrhoeae These results indicate that at antimicrobial doses, the test compounds exert 382	  
minimal toxicity towards host cells.  383	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 384	  
DISCUSSION 385	  
 386	  
Insight into the mode of antibacterial action of Cu(btsc) complexes. 387	  
Dynamics of “Cu-boosting” by Cu(btsc) complexes. The use of lipophilic ligands to 388	  
deliver metal ions into cells is an established concept, particularly in the detection and 389	  
intervention of cancers (35). In terms of antimicrobial applications, this concept has been 390	  
demonstrated by the use of zinc pyrithione (Zn-PYT) as an antifungal in soaps and shampoos. 391	  
The mode of action of Zn-PYT depends on transchelation with free Cu ions, presumably from 392	  
the extracellular environment, and subsequent delivery of these Cu ions into the target organism 393	  
(36). Coordination complexes that act as carriers for Cu ions are now being increasingly 394	  
investigated as a novel approach to combat bacterial infections (9, 13-15). 395	  
The bis(thiosemicarbazone) family of Cu carriers displays anticancer activities (37). 396	  
There is also interest in their potential as neurotherapeutics and as imaging agents for hypoxia. 397	  
Our group and others have now demonstrated that Cu(btsc) complexes are also promising 398	  
antimicrobials (13-15). However, while studies with mammalian systems have established the 399	  
action of these complexes as agents that alter the bioavailability of Cu, studies with bacteria have 400	  
not been equally conclusive, as the final Cu content of treated bacteria did not always correlate 401	  
with survival or viability (13, 15). These studies have focused on the total amounts of Cu at the 402	  
‘end point’ (eg. the ICP OES measurements in Figure 4A) but the present work suggested that 403	  
the kinetics of Cu influx and potential efflux by detoxification systems must also be considered 404	  
(Figure 8). This model is likely to be universal to all lipophilic Cu carriers and not limited to 405	  
those containing btsc ligands. 406	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Our results using E. coli showed that both Cu(gtsm) and Cu(atsm) enter the bacterial 407	  
cytoplasm more rapidly than do ionic Cu salts. These complexes are membrane-permeable, 408	  
probably via passive diffusion as an uptake system has not been identified (38). As these 409	  
complexes are uncharged, they would equilibrate rapidly across bacterial membranes and would 410	  
not accumulate as intact molecules to a high intracellular concentration. However, reduction of 411	  
the Cu(II) center and subsequent dissociation as bioavailable Cu(I) ion would generate a 412	  
powerful mass-action effect (Figure 8). This thermodynamically-driven influx of Cu ions may 413	  
overwhelm basal Cu tolerance and cause Cu poisoning. By comparison, the more restricted entry 414	  
of ionic Cu salts may allow activation of dedicated Cu detoxification mechanisms, which would 415	  
enable the bacterial cell to amass and, more importantly, survive higher final amounts of total 416	  
Cu.  417	  
The above model extends to the observed difference between the antibacterial activities 418	  
of Cu(gtsm) and Cu(atsm). While studies with mammalian systems suggest little intracellular 419	  
dissociation of bioavailable Cu ions from Cu(atsm) (21-23), our work with E. coli indicated that 420	  
it does occur, although it is less efficient than the equivalent process from Cu(gtsm). We cannot 421	  
discount possible variations in the rates of membrane penetration by the two complexes as a 422	  
result of subtle differences in lipophilicity (39). Nevertheless, it is more likely that, as a 423	  
consequence of a lower Cu(II)/Cu(I) mid-point potential for Cu(atsm) (Figure 1), the rate of 424	  
reduction (and, subsequently, dissociation) of Cu from Cu(atsm) is also lower. The bacterial cell 425	  
thus has more time to respond and detoxify the excess Cu, resulting in a lower antibacterial 426	  
potency of Cu(atsm).  427	  
Our results with MtrCDE-overexpressing strains of N. gonorrhoeae (Table 3) also 428	  
indicate that potential efflux of Cu(gtsm) and Cu(atsm) as intact molecules out of the cytoplasm 429	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must not be overlooked. Cu(gtsm) rapidly and efficiently dissociates within the cytoplasm and 430	  
thus this complex may evade active export by promiscuous efflux transporters. By comparison, 431	  
Cu(atsm) may linger as an intact molecule and thus be exported prior to dissociation and 432	  
subsequent release of bioavailable Cu(I) ions (Figure 8). This removal of Cu(atsm) from the 433	  
cytoplasm, either by MtrCDE or other efflux systems, would further reduce its antibacterial 434	  
efficacy. Although we have not tested this idea directly, the AcrAB-TolC multi-drug efflux 435	  
pump system (ref) it is likely that in this transporter will contribute to the observed resistance of 436	  
this bacterium to Cu(atsm) (40).  437	  
Correlation between bacterial physiology and susceptibility to Cu(btsc) complexes. The 438	  
antibacterial activity of Cu(btsc) complexes has now been tested against several important 439	  
human pathogens, including S. pneumoniae, H. influenzae, uropathogenic E. coli, Salmonella 440	  
(Table 2), as well as M. tuberculosis (14) and S. aureus (15). Not all of these showed equal 441	  
promise as targets for Cu(btsc) therapeutics, but all showed less susceptibility when compared 442	  
with N. gonorrhoeae. The explanation for these differences may relate to bacterial physiology. 443	  
Compared with most other bacterial pathogens, N. gonorrhoeae possesses a Cu 444	  
detoxification system that is unusually underdeveloped. It consists of a single Cu efflux pump, 445	  
CopA, and no additional cytoplasmic or periplasmic accessories (25). Importantly, Cu does not 446	  
induce the expression of the copA gene. Thus, while gonococcal CopA may participate in general 447	  
maintenance of Cu levels during regular metabolism (25, 41), it may be unable to confer 448	  
resistance to severe Cu stress. This absence of an inducible resistance system coincides with the 449	  
availability of targets of poisoning by Cu or Cu(btsc) complexes (Figure 8). These targets 450	  
include iron-sulfur (Fe-S) cluster-containing enzymes such as coproporhyrinogen(III) oxidase in 451	  
the pathway for heme biosynthesis (41). In addition, N. gonorrhoeae depends on two NADH 452	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dehydrogenases that are both susceptible to inhibition by Cu(btsc) complexes (13). As a 453	  
consequence, N. gonorrhoeae displays hypersensitivity to inhibition by Cu salts and Cu(btsc) 454	  
complexes, particularly Cu(gtsm) (Tables 1 – 3). 455	  
In E. coli, major targets of Cu poisoning are available, such as the Fe-S cluster enzymes 456	  
fumarase in the TCA cycle and isopropylmalate dehydratase in the pathway for branched-chain 457	  
amino acid synthesis (42). However, this bacterium also possesses sophisticated and robust, 458	  
inducible defenses against Cu toxicity (24). In addition, E. coli uses a versatile respiratory 459	  
electron transport system and fermentative systems that are less sensitive to Cu(btsc) complexes. 460	  
These arguments correlate well with our finding that E. coli is more resistant to inhibition by 461	  
Cu(btsc) complexes, even Cu(gtsm) (Table 2). Similarly, the Cu detoxification system in S. 462	  
pneumoniae is relatively well-developed compared with the system in N. gonorrhoeae. However, 463	  
S. pneumoniae has a relatively low dependence on Fe-S cluster enzymes and it does not contain a 464	  
respiratory chain. This may explain the limited sensitivity of this bacterium to Cu(atsm) and 465	  
Cu(gtsm) (Table 2). For these Cu-tolerant bacteria, the antimicrobial efficacy of Cu delivery 466	  
agents might be enhanced if used in conjunction with a CopA antagonist to trap excess Cu ions.  467	  
 468	  
Cu delivery agents as a novel concept for the topical treatment of N. gonorrhoeae.  469	  
Gonorrhea is the second most prevalent sexually transmissible infection worldwide and 470	  
management of this disease represents significant challenge to public health. There is no vaccine 471	  
and thus antibiotic treatment remains the only method to control the spread of infection. 472	  
However, MDR strains have developed resistance to virtually all first-line antibiotics (43). Our 473	  
work suggests that delivery of bioavailable Cu ions may represent a new approach to combat 474	  
gonococcal infections. The application of copper in the cervix and vagina is an established 475	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concept and intrauterine devices containing elemental copper is one of the most common and 476	  
most effective non-hormonal contraceptives worldwide (44). Here we showed that Cu salts and 477	  
Cu(btsc) complexes did not affect the viability of cervical epithelial cells in vitro at 478	  
concentrations that were inhibitory to the gonococcus (Figure 7). Moreover, Cu salts and 479	  
Cu(btsc) complexes were ineffective against lactic acid bacteria, as exemplified by Lactobacillus 480	  
acidophilus (see Table 2), suggesting that Cu delivery agents can be used to target gonococci 481	  
without significantly affecting the commensal flora. Crucially, unlike other bacterial pathogens 482	  
that have been identified as potential targets for treatments by Cu delivery agents, including M. 483	  
tuberculosis (14), S. aureus (15), and Cryptococcus neoformans (9), N. gonorrhoeae is primarily 484	  
an extracellular mucosal pathogen that colonises surfaces of the genitourinary epithelium. 485	  
Gonococcal infections are thus amenable to topical drug formulations and would bypass many of 486	  
the challenges of a systemic route for the delivery of Cu. 487	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TABLES 654	  
 655	  
Table 1. Antibacterial activity of several Cu complexes against N. gonorrhoeae.  656	  
 657	  
Complexa MIC (µM) 
Cu(gtsm) 0.10 
Cu-pyrithione 0.13 
Cu(atsm) 0.80 
Cu-neocuproine 0.80 
Cu-disulfiram 15 – 20  
Cu salt 250 
 658	  
aThe complexes were prepared and their concentrations standardised as described in Materials 659	  
and Methods. 660	  661	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Table 2. Susceptibility of select bacterial pathogens to Cu(atsm) and Cu(gtsm).  662	  
 663	  
Organisma 
MIC (µM) 
Cu(atsm) Cu(gtsm) 
N. gonorrhoeae 0.8 0.1 
H. influenzae 10 1 
S. aureus >10 1.5 
S. pneumoniae >10 2 
L. acidophilus >25 5  
S. Typhimurium >25 >25 
E. coli >25 >25 
 664	  
aStrain information is available in Materials and Methods. 665	  666	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Table 3. Susceptibility of multidrug-resistant strains of N. gonorrhoeae to Cu salt, Cu(atsm) and 667	  
Cu(gtsm). Data presented were averaged from three independent experiments. Standard 668	  
deviations from the mean are shown in brackets. 669	  
 670	  
 671	  
 672	  
aAntibiotic resistance profiles of select strains are shown in Table S1. 673	  674	  
 
Straina Ref 
MIC (µM) 
 Cu salt Cu(atsm) Cu(gtsm) 
antibiotic- 
sensitive 
1291 (45) 250 (0) 0.8 (0.1) 0.1 (0.0) 
FA1090 (46) 250 (0) 0.9 (0.1) 0.1 (0.0) 
F62 (47) 250 (0) 0.7 (0.1) 0.1 (0.0) 
antibiotic- 
resistant 
MS11 (48) 250 (0) 2.3 (0.2) 0.1 (0.0) 
FA6140 (49) 250 (0) 3.0 (0.3) 0.1 (0.2) 
F89 (29) 250 (0) 1.7 (0.3) 0.1 (0.0) 
H041 (30) 250 (0) 1.9 (0.2) 0.1 (0.0) 
 FA19 (50) 250 (0) 0.9 (0.1) 0.1 (0.0) 
 DW120 (32) 250 (0) 2.2 (0.2) 0.1 (0.0) 
 KH15 (32) 250 (0) 2.7 (0.3) 0.1 (0.0) 
 KH14 (33) 250 (0) 0.7 (0.1) 0.1 (0.0) 
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FIGURES 675	  
 676	  
 677	  
Figure 1. Structure of Cu(btsc) complexes. Mid-point reduction potentials are vs Ag/AgCl.21 678	  
 679	  680	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 681	  
 682	  
Figure 2. Time-dependent bactericidal effects of Cu(btsc) complexes (1 µM each) against N. 683	  
gonorrhoeae 1291. Number of surviving CFUs was plotted against time post-challenge. The 684	  
effects of Cu salt (1 µM) and DMSO control were also shown. Each data point was averaged 685	  
from three independent replicates. Error bars represent ± standard deviation from the mean.  686	  687	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 688	  
 689	  
Figure 3. Inhibitory effects of Cu(btsc) complexes on aerobic respiration by E. coli. (A) 690	  
Amounts of O2 consumed by whole bacteria over 15 min in the presence of various Cu sources 691	  
(50 µM). (B) Rates of NADH oxidation by isolated membrane vesicles in the presence of 692	  
Cu(gtsm) (0 – 50 µM). (A and B) Results were shown as a percentage of the unchallenged 693	  
control. Each data point was averaged from three independent replicates. Error bars represent ± 694	  
standard deviation from the mean. 695	  696	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 697	  
 698	  
Figure 4. Effects of Cu(btsc) complexes on (A) total intracellular Cu content and (B) plating 699	  
efficiency of E. coli, presented as a percentage of vs. the unchallenged control. (A and B) 700	  
Treatment time was 24 h. Each data point was averaged from three independent replicates. Error 701	  
bars represent ± standard deviation from the mean. 702	  703	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 704	  
 705	  
Figure 5. Release of Cu ions from Cu(btsc) complexes. (A) Cu detoxification system in E. coli. 706	  
To determine the presence of bioavailable Cu(I) ions in the cytoplasm, the promoter region of 707	  
copA (in red) was fused to a promoterless lacZ gene (in grey). IM, inner membrane; OM, outer 708	  
membrane. (B) Response of PcopA-lacZ fusion to divalent transition metal ions (supplied as 709	  
chloride salt, 100 µM each) at t = 2 h post-exposure. (C) Dose-dependent induction of the copA 710	  
promoter. β-galactosidase activity was assayed at t = 2 h post-exposure. (D) Time-dependent 711	  
induction of the copA promoter in response to Cu salt (100 µM), Cu(gtsm) (10 µM) or Cu(atsm) 712	  
(25 µM). (B – D) Each data point was averaged from three replicates. Error bars represent ± 713	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standard deviation from the mean. The results shown were representative of at least three 714	  
independent experiments. 715	  716	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 717	  
 718	  
Figure 6. Susceptibility of E. coli mutant strains to (A) Cu salt, (B) Cu(gtsm), and (C) Cu(atsm) 719	  
as determined by efficiency of plating on solid medium. Serial dilutions of bacteria were shown 720	  
on the left. Concentrations of the various Cu sources were indicated at the bottom. Treatment 721	  
time was 24 h. The results shown were representative of at least three independent experiments.  722	  723	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 724	  
 725	  
Figure 7. Effects of Cu(btsc) complexes on (A) total cell counts and (B) cell viability of ME-180 726	  
cervical epithelial cells. The treatment time was 24 h. The viability of cells in panel B was 727	  
determined using the same corresponding set of cells used for counting in panel A. The number 728	  
of replicates is shown above each column. Error bars represent ± standard deviation from the 729	  
mean. There was no statistically significant difference in the cell counts of viability from the 730	  
different treatments. The results shown were representative of at least three independent 731	  
experiments. DMSO (5 v/v %, columns a) and Triton X-100 (0.1 v/v %, columns b) were also 732	  
included as positive controls of cell death. 733	  734	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 735	  
 736	  
Figure 8. Schematic representation for the antibacterial action of Cu(btsc) complexes. A. 737	  
Mechanisms of action: (i) Inhibition of membrane-bound NADH dehydrogenases of the electron 738	  
transport chain by the intact Cu(btsc) complex, (ii) reduction of the CuII centre and dissociation 739	  
of CuI as bioavailable ions, and (iii) poisoning of enzymes by CuI ions. B. Mechanisms of 740	  
tolerance: (i) Efflux of the intact Cu(btsc) complex by the MtrCDE efflux pump or other 741	  
promiscuous drug transporters, (ii) efflux of bioavailable CuI ions, and (iii) activation of other 742	  
dedicated Cu ion tolerance genes. 743	  
